Clinical applications of therapeutic agents for long-term management of heart failure have been hindered by the poor delivery efficiency. Here, the authors propose a myocardium-targeted strategy based on inhalable cardiac-targeting peptide-modified nanomedicine for the pharmacological treatment of heart failure.
- Haobo Weng
- Weijuan Zou
- Xianhong Shu
